Company Overview and News

 
OCL India Limited - Resignation

2018-05-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
OCL India Limited - Trading Window

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
OCL India Limited - Results

2018-01-20 nseindia

 
OCL India Limited - Trading Window

2018-01-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
OCL India Limited - Shareholders meeting

2017-12-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
OCL India Limited - Shareholders meeting

2017-12-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
OCL India Limited - Financial Result Updates

2017-11-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Mannapuram, BHEL, IOB, Tata Coffee,results today

2017-11-06 thehindubusinessline
AB Capital, Ballarpur, Balrampur Chini, BHEL, Castrol, Cipla, Dalmia Bharat, DCM Shriram, Dhampur Sugar, Essel Propack, Filatex India, Future Retail, GTL, Glaxo Consumer, HFCL, Himtsingka Seide, IOB, Jindal Saw, L&T Tech, Liberty Shoes, Manappuram Finance, Majesco, NLC India, OCL India, Prism Cement, Tata Coffee, Thermax VIP and Wabco India are among about 80 firms that will declare September quarter numbers on Tuesday.

 
Market update: 117 stocks hit fresh 52-week high on NSE; ICICI Bank top gainer, Axis most active

2017-11-01 moneycontrol
The Nifty and the Sensex continued their respective bull run in the afternoon trade hitting fresh record highs. The Nifty50 zoomed close to 100 points, trading at 10435.85 while the Sensex jumped 377 points at 33590.

 
Market update: 95 stocks hit fresh 52-week high on NSE as midcaps outperform; Yes Bank top gainer

2017-10-30 moneycontrol
The Nifty as well as the Sensex continued to hold on to their respective morning gains with the Nifty adding 50 points or 0.49 percent while the Sensex gained 0.43 percent and was trading at 33,296.17. The Nifty midcap index continued to outperform the broader indices gaining 1.3 percent led by MRF, Bata India, Just Dial, IDBI Bank, Oriental Bank of Commerce and Voltas.

 
Market update: Maruti hits new 52-week high; SBI, Jet Airways top gainers, ICICI most active

2017-10-30 moneycontrol
The Indian equity market opened the week on a bullish note with the Nifty jumping 55.40 points or 0.54 percent while the Sensex gained 164.59 points at 33,2321.81. The Nifty midcap index was the outperforming sector which was up 1.18 percent led by Union Bank of India, Syndicate Bank, Bata India and Allahabad Bank.

 
Market update: United Spirits zooms over 22%; Maruti hits record high; ICICI most active

2017-10-27 moneycontrol
The Nifty as well as the Sensex in the afternoon trade on Friday held on to their respective gains with the Nifty trading 0.05 percent higher at 10349.30 while the Sensex was up 90.35 points at 33237.71 largely dragged by Bank Nifty which fell 0.26 percent.

 
Market update: RIL, Jubilant Food hit new 52-week high; LT top gainer, SBI most active

2017-10-26 moneycontrol
The market in the afternoon trade recovered all the morning losses with the Sensex gaining 88 points, up 0.27 percent while the Nifty added 0.34 percent, a gain of 34 points. The midcap index continued to outperform the broader indices which added 0.58 percent led by IFCI, IDBI Bank, Steel Authority of India and Ashok Leyland.

 
OCL India Limited - Results

2017-10-24 nseindia

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...